Statin vs PCSK9 Inhibitor
Statins reduce LDL/ApoB by 30–55% and remain first-line. PCSK9 inhibitors reduce LDL by an additional 50–60% on top of statin and are reserved for high-risk candidates not at goal on maximum-tolerated statin.
Statin is the provider-reviewed first-line for LDL/ApoB reduction.
PCSK9 inhibitor is appropriate when high-risk candidates remain above goal on maximum-tolerated statin.
Educational. Final pathway selection is provider-reviewed via synchronous video consultation against your biomarkers, history, and goals.
Frequently asked
Can they be combined?
Yes — PCSK9 inhibitors are typically added to statin therapy.
Are PCSK9 inhibitors first-line?
No — except in rare statin-intolerant or familial hypercholesterolemia cases.
Take the optimization assessment.
The adaptive assessment maps your symptoms, history, and goals to candidate pathways — and routes you into provider review.
Begin assessment